These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27803737)

  • 1. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.
    Ventura-Cots M; Concepción M; Arranz JA; Simón-Talero M; Torrens M; Blanco-Grau A; Fuentes I; Suñé P; Alvarado-Tapias E; Gely C; Roman E; Mínguez B; Soriano G; Genescà J; Córdoba J
    Therap Adv Gastroenterol; 2016 Nov; 9(6):823-835. PubMed ID: 27803737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
    Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
    J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
    Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
    Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
    Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
    Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
    Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
    J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.
    Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF
    Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
    Dadsetan S; Sørensen M; Bak LK; Vilstrup H; Ott P; Schousboe A; Jalan R; Keiding S; Waagepetersen HS
    Biochem Pharmacol; 2013 Jan; 85(1):115-23. PubMed ID: 23103564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
    Rahimi RS; Safadi R; Thabut D; Bhamidimarri KR; Pyrsopoulos N; Potthoff A; Bukofzer S; Bajaj JS
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2626-2635.e7. PubMed ID: 33069881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
    Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
    Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
    J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
    Wang X; Tseng J; Mak C; Poola N; Vilchez RA
    Clin Pharmacokinet; 2021 Dec; 60(12):1557-1567. PubMed ID: 34125423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
    Tromm A; Griga T; Greving I; Hilden H; Hüppe D; Schwegler U; Micklefield GH; May B
    Hepatogastroenterology; 2000; 47(32):473-7. PubMed ID: 10791216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.
    Wright G; Vairappan B; Stadlbauer V; Mookerjee RP; Davies NA; Jalan R
    Liver Int; 2012 Mar; 32(3):410-9. PubMed ID: 22151131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
    Stravitz RT; Gottfried M; Durkalski V; Fontana RJ; Hanje AJ; Koch D; Hameed B; Ganger D; Subramanian RM; Bukofzer S; Ravis WR; Clasen K; Sherker A; Little L; Lee WM;
    Hepatology; 2018 Mar; 67(3):1003-1013. PubMed ID: 29080224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
    Wen J; Liu Q; Song J; Tong M; Peng L; Liang H
    Digestion; 2013; 87(2):132-8. PubMed ID: 23485720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration.
    Ghabril M; Zupanets IA; Vierling J; Mantry P; Rockey D; Wolf D; O'Shea R; Dickinson K; Gillaspy H; Norris C; Coakley DF; Mokhtarani M; Scharschmidt BF
    Clin Pharmacol Drug Dev; 2013 Jul; 2(3):278-84. PubMed ID: 27121790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.